financetom
Business
financetom
/
Business
/
Amgen Says Plaque Psoriasis Drug for Pediatric Use Available in US
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amgen Says Plaque Psoriasis Drug for Pediatric Use Available in US
Aug 20, 2024 7:09 AM

09:44 AM EDT, 08/20/2024 (MT Newswires) -- Amgen ( AMGN ) said Tuesday that Otezla is now available in the US for the treatment of moderate to severe plaque psoriasis in patients aged six to 17.

The company said the US Food and Drug Administration has not approved any other oral medications for the treatment of the disease in this age group.

Price: 328.95, Change: +0.98, Percent Change: +0.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Canada's Boyd Group Services Q2 sales miss estimates
Canada's Boyd Group Services Q2 sales miss estimates
Aug 13, 2025
Overview * Boyd Group Q2 sales up 0.2%, missing analyst expectations, per LSEG data * Adjusted EPS for Q2 missed consensus, reflecting ongoing profitability challenges * Company's location count surpasses 1,000, driven by acquisitions and new openings Outlook * Boyd Group says achieved modest positive same-store sales growth so far in Q3 2025 * Company aims for $100 mln cost...
Cannabis firm Organigram's Q3 revenue beats estimates
Cannabis firm Organigram's Q3 revenue beats estimates
Aug 13, 2025
Overview * Organigram fiscal Q3 net rev rises 72% yr/yr, beating analyst expectations * Adjusted EBITDA for fiscal Q3 grows 64% yr/yr, driven by higher revenue * Company expands U.S. presence, generating revenue and increasing exports Outlook * Organigram expects adjusted gross margin to improve with Motif synergies * Company anticipates sustained profitability and free cash flow in near-term *...
European Wax Center misses Q2 revenue, beats adjusted net income estimates
European Wax Center misses Q2 revenue, beats adjusted net income estimates
Aug 13, 2025
Overview * European Wax Center ( EWCZ ) Q2 revenue falls 6.6%, missing analysts' expectations * Adjusted net income rises 5.6%, beating estimates, per LSEG data * Adjusted EBITDA increases 4.7%, surpassing analysts' forecasts, per LSEG data Outlook * Company sees fiscal 2025 system-wide sales of $940 mln to $950 mln * European Wax Center ( EWCZ ) expects fiscal...
Copyright 2023-2026 - www.financetom.com All Rights Reserved